This interview with a UK-based key opinion leader (KOL) offers comprehensive insights into current disease landscape for patients with anemia in chronic kidney disease (CKD), and expectations regarding emerging pipeline therapies. The discussion covers the current treatment paradigm with emphasis on erythropoiesis-stimulating agents (ESAs) and iron, as well as perspectives on the hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor class, challenges to its adoption, and its prospective roles in future disease management.

This interview was conducted on 28 May, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.